A
Allotera TherapeuticsTherapeutics
Allotera Therapeutics develops allogeneic cell therapies for treating serious diseases.
$35M
Investor undisclosed
A $35M Series A for allogeneic cell therapy signals that off-the-shelf cell manufacturing is finally hitting the risk/reward sweet spot for investors—manufacturing scale and immune tolerance are becoming solvable, not theoretical. At this stage and size, Allotera is likely burning cash on GMP manufacturing, clinical trial setup, and IP moats around their allogeneic platform. If you're building in adjacent biotech (gene therapy, regenerative medicine, or even synthetic biology), watch whether they can actually solve the cost-per-dose problem that's killed previous allogeneic plays—that's the real gate.